DB Insurance Secures Exclusive Rights for Chronic Disease In-Kind Benefits and Drug Therapy Coverage

(Seoul=Yonhap Infomax) Yun Gu Lee – DB Insurance Co., a leading South Korean non-life insurer, announced on the 26th that it has obtained exclusive rights for its new chronic disease insurance products, including "in-kind benefit chronic disease diagnosis coverage," "chronic disease drug therapy coverage," and an "overseas heavy ion therapy payment agency service."

The in-kind benefit chronic disease diagnosis coverage, granted a six-month sales exclusivity, comprises three products tailored to specific conditions:

• For customers diagnosed with hypertension, the company provides a ring-type blood pressure monitor (CART BP) and an electronic blood pressure monitor.
• For those diagnosed with dyslipidemia, a home-use body composition analyzer (InBody Dial) is offered.
• For diabetes patients, a continuous glucose monitoring device is provided.

Additionally, the product includes care calls from specialized medical staff for mild chronic diseases and support for managing key health indicators such as blood pressure, body composition, and blood glucose.

The new chronic disease drug therapy coverage, which has secured a nine-month exclusivity period, offers three types of coverage: If a policyholder is definitively diagnosed with mild hypertension, dyslipidemia, or diabetes after the policy start date and continues annual drug therapy while maintaining health indicators within the mild range, the insured amount is paid once per year for up to five years.

Separately, DB Insurance has also obtained a nine-month exclusive right for its newly introduced overseas heavy ion therapy payment agency service. Under this service, if a customer assigns their insurance claim for heavy ion cancer radiotherapy to a concierge company, the concierge will prepay the corresponding amount directly to a Japanese medical institution.

A DB Insurance official stated, "These new products are designed to naturally encourage ongoing treatment and healthy lifestyle habits, which are essential for chronic disease management, thereby contributing to customers' health." The official added, "While heavy ion therapy is highly anticipated for its effectiveness, the high cost remains a barrier. This new service is expected to significantly improve access to treatment and ease the burden of high medical expenses for our customers."

yglee2@yna.co.kr

(End)